About
Company Overview
Milestones
Board of Directors
Management
Organizational Chart
CSR
R&D
Pipeline
Adagloxad simolenin
OBI-833
OBI-888
OBI-999
OBI-3424
OBI-858
OBI-868
News
News
Video Library
External Links
Investors
About
Company Profile
Corporate Governance
Stakeholder
Company Presentation
News & Events
Announcements
Event Calendar
MOPS (Market Observation Post System)
Financial Information
Annual Report
Financial Report
Monthly Revenues
Shareholder Information
Stock Quote
Shareholder Services
IR Contacts
Investor Tools
Investor FAQ
Download Library
RSS Feeds
Careers
Contact
LL
April 19, 2018
Published by
LL
at
April 19, 2018
Categories
News
News 2018
OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors
[…]
December 22, 2017
Published by
LL
at
December 22, 2017
Categories
News
News 2017
OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.
[…]
October 5, 2015
Published by
LL
at
October 5, 2015
Categories
News
News 2015
OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan
[…]
August 31, 2015
Published by
LL
at
August 31, 2015
Categories
News
News 2015
OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016
[…]
1
2
3
4
Next page